Use of tumor infiltrating lymphocytes to treat patients with NSCLC refractory to anti-PD-1 antibodies

摘要

The present invention provides an improved and/improved or shortened process and method for preparing TILs to prepare a therapeutic population of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is It is refractory to treatment with anti-PD-1 antibodies.